Financial Toxicity and Quality of Life in Patients With TGCT
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
This is a cross-sectional, observational study employing validated questionnaires to investigate financial toxicity in subjects with testicular germ cell tumors (TGCT). As background, TGCTs are the most common malignancies among men from age 15-35. Treatment is highly curative, but often consists of intensive multi-cycle chemotherapy with significant potential for physical toxicity. The treatment course itself is disruptive and long term physical and mental health consequences can increase risk for financial toxicity. Thus, we aim to study financial toxicity in both patients with TGCT actively receiving treatment and in TGCT survivors. There will be two separate cohorts: Cohort 1 will consist of subjects with recently diagnosed TGCT who will undergo multi-agent, multi-cycle chemotherapy and Cohort 2 will consist of subjects who have completed chemotherapy and are long-term survivors.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age > 18 years of age
- Patients with histologically or clinically confirmed germ cell tumor.
- Completed treatment for germ cell tumor with multicycle (> 2 cycles) / multiagent chemotherapy.
- Within years 1-5 of surveillance since Day 1 of last cycle of chemotherapy
- Signed informed consent
Exclusion criteria
-
Long-term survivors
- Patients undergoing active chemotherapy
- Patients who did not complete 1st line chemotherapy.
Trial design
24 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Deepak Pruthi, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal